Harry Kleanthous | Executive Vice President, Vaccines R&D Strategy & External Innovation
SK Bioscience

Harry Kleanthous, Executive Vice President, Vaccines R&D Strategy & External Innovation, SK Bioscience

Appearances:



Day 2 - Wednesday 3rd April @ 17:10

Development of a broadly protective pan-sarbecovirus nanoparticle vaccine

last published: 27/Mar/24 22:15 GMT

back to speakers